

BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL)

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 18/10/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
RADIATION

Study information

Scientific Title

BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL)

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

Interventions

Standard radiotherapy versus low dose radiotherapy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

30/04/1997

Completion date

31/12/2005

Eligibility

Key inclusion criteria

1. Any patient receiving local radiotherapy (RT) where the aim of the treatment is local control of that lymphoma, whether as radical treatment of Stage I disease, consolidation therapy after chemotherapy or palliation
2. Histological diagnosis of NHL
3. Aged 18 years or over
4. Able to give informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

1000

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

30/04/1997

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

British National Lymphoma Investigation (BNLI) (UK)

Sponsor details

CRC and UCL Cancer Trials Centre
222 Euston Road
London
United Kingdom
NW1 2DA
+44 (0)20 7679 8060
bnli@ctc.ucl.ac.uk

Sponsor type

Charity

Website

<http://www.bnli.ucl.ac.uk>

Funder(s)

Funder type

Charity

Funder Name

British National Lymphoma Investigation (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes